StockData

Inovio Pharmaceuticals vs Lisata Therapeutics

INO and LSTA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How INO and LSTA compare

Inovio Pharmaceuticals is the larger company, worth 18 times as much as Lisata Therapeutics ($169M against $9.4M).

Lisata Therapeutics grew revenue faster over the last twelve months (−90.7% versus −100% for Inovio Pharmaceuticals).

Lisata Therapeutics scores higher on the StockData Score (6 against 4 for Inovio Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricINOLSTA
Size and price
Market cap$169M$9.4M
Share price$1.63$1.04
Change, 1 year−20.5%−50.9%
Change, 5 years−98.1%−92.9%
Beta (5Y)−0.26−1.59
Employees2721
StockData Score
Total score46 (better)
Valuation score01 (better)
Growth score00
Performance score00
Health score45 (better)
Dividend score00
Valuation
P/S–93.7×
P/B38.6×1.1× (better)
FCF yield−47.9% (better)−131%
Growth
Revenue growth (TTM)−100%−90.7% (better)
Revenue growth, 5Y average−61.2%–
Profitability
Operating margin–−16427%
Net margin–−14621%
FCF margin–−12323%
Return on equity−410%−99.9% (better)
Return on invested capital–−1645%
Financial health
Debt / equity0.000.00
Current ratio1.003.69 (better)
Altman Z-score−55.23 (better)−74.81
Piotroski F-score11
Dividends and buybacks
Buyback yield−22.6%−6.3% (better)
Shareholder yield−22.6%−6.3% (better)
Ownership
Held by institutions31.7%12.1%
Held by insiders0.38%11.6%
Short interest, % of float21.5%0.43%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.